| |
Unleash the Full Potential of Your Data! Our BioELN Solution maximizes your success with efficient resources and knowledge management. Transform data into discoveries with Signals Notebook. Learn more in our white paper.
|
|
Today's Big NewsMay 9, 2023 |
|
Wednesday, May 17, 2023 2:00pm ET / 11:00am PT Join this webinar to learn more about the opprtunity medical affairs teams and medical science liaisons (MSLs) have to engage with HCPs in clinical discussions and bridge care gaps by providing crucial insights into evidence-based medicine. Register now to learn more.
|
|
| By Eric Sagonowsky,Max Bayer,Kevin Dunleavy,Zoey Becker,Fraiser Kansteiner,Andrea Park,Annalee Armstrong,Ben Adams,Gabrielle Masson,James Waldron,Nick Paul Taylor The times are changing in biopharma. We hope our selections for this year's Most Influential People in Biopharma special report reflect the trends many of our readers are seeing in the industry. |
|
|
|
By Nick Paul Taylor,Max Bayer Novavax is reducing its head count by 25%. After trying to cut costs without laying off staff, the vaccine company has now accepted it will need to part ways with hundreds of employees to align its spending with the dwindling size of the COVID-19 opportunity. |
By Andrea Park Genomic sequencing can help match cancer patients to the most effective treatments based on their specific genetic makeup—but only if they have access to the necessary testing. Thermo Fisher Scientific and Pfizer, which have joined forces to expand the global reach of next-generation sequencing technologies. |
By Kevin Dunleavy Pfizer’s proposed $43 billion acquisition of Seagen two months ago was the largest deal in biopharma since 2019 but it came during a period when M&A activity has been limited. Analysts from EY and West Monroe however believe that the M&A market is about to grow because of a confluence of factors. |
|
Tuesday, May 23, 2023 | 2pm ET / 11am PT Clinical trials are complex, time-consuming, and costly. But what if you could use simulation to guide your decisions and optimize your trial design? In this webinar, we'll discuss the power of simulation-guided trial design (SGTD) and explain its benefits to clinical development strategies. Register now to join us.
|
|
By James Waldron Last month, Fierce Biotech told you about an unknown number of layoffs due to hit Takeda employees as the Japanese pharma moves away from early-stage R&D work in adeno-associated virus-based gene therapies and rare hematology. Now, we’ve got a better sense of the workforce impact. |
By Angus Liu Eli Lilly’s R&D chief is openly attacking a widely disputed clause in the Inflation Reduction Act that subjects small- and large-molecule medicines to different price negotiation timelines. Meanwhile, the drug industry is also preparing legal arguments to challenge how the U.S. government implements the new law, Reuters reports. |
By Conor Hale First launched in May 2022, the company’s Shield test searches for evidence of the disease by analyzing small fragments of tumor DNA found floating in the bloodstream. |
By Max Bayer FibroGen is taking on Fortis Therapeutics' sole asset, an antibody drug conjugate for prostate cancer and multiple myeloma, to fortify a pipeline that has to-date been mainly siloed towards anemia and fibrotic diseases. |
By Fraiser Kansteiner AstraZeneca’s heart, kidney and diabetes drug Farxiga lagged its Eli Lilly counterpart last year after Jardiance bagged an approval to treat a wider spectrum of heart failure patients. But a fresh green light for AstraZeneca’s med could put the SGLT2 rivals neck and neck once again. |
By Gabrielle Masson EQRx is abandoning its plan to provide drugs that are typically expensive at lower prices. The biotech is also cutting ties with two of its partners, letting go of 170 staff members and slashing all assets from its pipeline except one. |
By Andrea Park They say the eyes are the window to the soul, but a newly launched company is hoping they can also shed some light on early signs of disease. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we're continuing our miniseries on Narcan the nasal spray. It is the first naloxone product to be approved for use without a prescription. |
|
|---|
|
|
|
Thursday, May 25, 2023 | 10:00am ET / 7:00am PT Join the webinar and discover our MVA technology platform and explore the advantages for development and manufacturing of multiple vaccines and cell and gene therapeutics. Register now.
|
|
| WhitepaperChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookDiscover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success. Sponsored by: EvidentIQ |
| ResearchWhat role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| WhitepaperThis paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| WhitepaperHow can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
